Bumper Offer - Urjas oil Just @ Rs. 1 X
Zifi 50 Readymix Oral Suspension 60ml is a prescription medicine that is available as a Suspension. Primarily, it is used for the treatment of Ear Infection, Tonsillitis, Bronchitis. Secondary and off-label uses of Zifi 50 Readymix Oral Suspension 60ml have also been mentioned below.
The right dosage of Zifi 50 Readymix Oral Suspension 60ml depends on the age, gender, and medical history of the patient. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Some other side effects of Zifi 50 Readymix Oral Suspension 60ml have been listed ahead. Such side effects of Zifi 50 Readymix Oral Suspension 60ml normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
Zifi 50 Readymix Oral Suspension 60ml's effect during pregnancy is Safe and Safe while nursing. In addition, Zifi 50 Readymix Oral Suspension 60ml's effects on the liver, heart and kidney are discussed below in the Zifi 50 Readymix Oral Suspension 60ml related warnings section.
Some other conditions that can be affected by Zifi 50 Readymix Oral Suspension 60ml are listed in the contraindications section below.
Drug interactions for Zifi 50 Readymix Oral Suspension 60ml have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Zifi 50 Readymix Oral Suspension 60ml, it is important to know that it is not safe while driving, and is not habit-forming.
Zifi 50 Readymix Oral Suspension 60ml is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Is the use of Zifi 50 Readymix Oral Suspension 60ml safe for pregnant women?
Zifi is safe to take during pregnancy.
Is the use of Zifi 50 Readymix Oral Suspension 60ml safe during breastfeeding?
Zifi is completely safe for breastfeeding women.
What is the effect of Zifi 50 Readymix Oral Suspension 60ml on the Kidneys?
Zifi has very mild side effects on the kidneys.
What is the effect of Zifi 50 Readymix Oral Suspension 60ml on the Liver?
Zifi is not harmful for the liver.
What is the effect of Zifi 50 Readymix Oral Suspension 60ml on the Heart?
You can take Zifi without any fear of damage to the heart.
Zifi 50 Readymix Oral Suspension 60ml should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zifi 50 Readymix Oral Suspension 60ml unless your doctor advises you to do so -
Is this Zifi 50 Readymix Oral Suspension 60ml habit forming or addictive?
No, you will not get addicted to Zifi 50 Readymix Oral Suspension 60ml.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Zifi 50 Readymix Oral Suspension 60ml as you may feel sleepy.
Is it safe?
Zifi 50 Readymix Oral Suspension 60ml is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, the use of Zifi 50 Readymix Oral Suspension 60ml in mental disorders is not effective.
Interaction between Food and Zifi 50 Readymix Oral Suspension 60ml
Taking Zifi 50 Readymix Oral Suspension 60ml with food does not cause any problems.
Interaction between Alcohol and Zifi 50 Readymix Oral Suspension 60ml
It is difficult to say anything about the effect of Zifi 50 Readymix Oral Suspension 60ml and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 839
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)